Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
Prostate cancer is a common cancer in men; for metastatic disease, it has a 5-year survival rate of 30%. No FDA-approved therapy for castrate-resistant prostate cancer (CRPC) known to improve survival was available until 2004, when based on a significant survival benefit over mitoxantrone, docetaxel...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
S. Karger AG
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398088/ |